Virax Biolabs Group (VRAX) Stock Price, News & Analysis

Company Overview

Virax Biolabs Group (NASDAQ: VRAX) is a clinical-stage biotechnology company focused on the research, development and manufacturing of next-generation vaccines targeting respiratory and other infectious diseases. Headquartered in Australia, the company leverages advanced viral vector platforms to create novel immunization solutions designed to induce both systemic and mucosal immunity. Virax Biolabs is publicly traded on the NASDAQ exchange under the symbol VRAX.

At the core of Virax Biolabs’ pipeline is a proprietary adenoviral vector platform, licensed exclusively from a leading academic institution, which serves as the backbone for intranasal and injectable vaccine candidates. The company’s preclinical and early-stage clinical programs span a range of pathogens, including emerging coronaviruses, seasonal influenza strains and respiratory syncytial virus (RSV). By focusing on mucosal delivery, Virax Biolabs aims to enhance localized immune responses in the respiratory tract, potentially reducing transmission as well as disease severity.

To support its R&D activities, Virax Biolabs operates a state-of-the-art cGMP manufacturing facility in Australia, enabling in-house production of clinical trial material and facilitating rapid scale-up capabilities. The company collaborates with universities, contract research organizations and global health partners to advance its vaccine candidates through regulatory pathways and into broader clinical studies. Its strategic presence in the Asia-Pacific region positions Virax Biolabs to address both regional public health needs and international market opportunities.

Virax Biolabs is guided by a management team with deep expertise in vaccine development, regulatory affairs and biologics manufacturing. Through its combination of proprietary technology, in-house production capacity and academic partnerships, the company seeks to deliver safe, effective and accessible vaccines that address unmet medical needs in respiratory and infectious disease prevention.

Key Stats

• Today's Range: $3.02 to $3.36
• 50-Day Range: $2.74 to $7.98
• 52-Week Range: $2.50 to $28.50
• Volume: 114,338 shs
• Average Volume: 637,030 shs
• Market Capitalization: $2.42 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $25.00
• Consensus Rating: Hold

Virax Biolabs Group Stock Analysis - MarketRank™

Virax Biolabs Group scored higher than 65% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.2 / 5
• Analyst Rating: Hold

Consensus Rating

Virax Biolabs Group has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, 1 buy rating, 1 hold rating, and 1 sell rating.

Upside Potential

Virax Biolabs Group has a consensus price target of $25.00, representing about 703.6% upside from its current price of $3.11.

Amount of Analyst Coverage

Virax Biolabs Group has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.3 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Virax Biolabs Group are expected to grow in the coming year, from ($10.00) to ($6.00) per share.

Price to Book Value per Share Ratio

Virax Biolabs Group has a P/B Ratio of 0.10. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

42.98% of the float of Virax Biolabs Group has been sold short.

Short Interest Ratio / Days to Cover

Virax Biolabs Group has a short interest ratio ("days to cover") of 0.19, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Virax Biolabs Group has recently decreased by 4.16%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Virax Biolabs Group does not currently pay a dividend.

Dividend Growth

Virax Biolabs Group does not have a long track record of dividend growth.

News and Social Media

• Score: 3.4 / 5
• News Sentiment: 1.50

News Sentiment

Virax Biolabs Group has a news sentiment score of 1.50. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.55 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 2 news articles for Virax Biolabs Group this week, compared to 1 article on an average week.

Search Interest

Only 1 people have searched for VRAX on MarketBeat in the last 30 days. This is a decrease of -89% compared to the previous 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Virax Biolabs Group insiders have not sold or bought any company stock.

Percentage Held by Insiders

45.10% of the stock of Virax Biolabs Group is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

8.61% of the stock of Virax Biolabs Group is held by institutions.

Company Calendar

• Last Earnings: 7/03/2026
• Today: 7/07/2026
• Fiscal Year End: 3/31/2027

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:VRAX
• CIK: 1885827
• Web: viraxbiolabs.com
• Phone: 44-0-20-7788-7414
• Fax: N/A
• Employees: 5
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Virax Biolabs Group: $25.00
• High Price Target: $25.00
• Low Price Target: $25.00
• Potential Upside/Downside: +722.4%
• Consensus Rating: Hold
• Rating Score (0-4): 2.00
• Research Coverage: 3 Analysts

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: $2.99 thousand
• Price / Sales: 811.41
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $31.45 per share
• Price / Book: 0.10

Miscellaneous

• Outstanding Shares: 797,000
• Free Float: 438,000
• Market Cap: $2.42 million
• Optionable: Not Optionable
• Beta: 1.35